EGFR and central nervous system cancer: We evaluated the diagnostic efficacy of serum EVs for glioma patients and found that EGFR+ EVs were able to diagnose glioma patients with high sensitivity and specificity (AUC 0.900, 95% CI 0.8064 ~ 0.9936, P <0.0001).